MoonLake Immunotherapeutics - Class A — Quarterly Financial Statistics (NASDAQ:MLTX) | MetaTrader

Open full chart

Financials

Overview Rapor Statistics Dividends

Quarterly Annual

Cash from operating activities -110.95 M-184.7 M38.14 M54.53 M44.54 M58.79 M 196.01 M Cash from investing activities -174.81 M-263.86 M56.25 M88.25 M88.4 M-29.91 M 202.99 M Cash from financing activities 183 K150.71 K73.12 M0480 K72.39 M 146 M Free cash flow -111.08 M-184.88 M38.1 M54.53 M44.54 M58.79 M 195.97 M

Haberler

MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal (NASDAQ:MLTX)

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day - Slideshow (NASDAQ:MLTX) 2026-02-23

MoonLake Immunotherapeutics (MLTX) Analyst/Investor Day Transcript

MoonLake hisseleri pozitif axSpA deneme verileriyle yükseldi

MoonLake stock surges on positive axSpA trial data

MoonLake hissesi InvestingPro Gerçeğe Uygun Değer çağrısı sonrası %63 yükseldi

MoonLake stock surges 63% after InvestingPro Fair Value call

MoonLake aksiyel spondiloartrit için olumlu faz 2 verisi açıkladı

MoonLake reports positive phase 2 axial spondyloarthritis data

ImageneBio, Dr. Porter-Brown’ı Tıbbi Direktör olarak atadı

ImageneBio appoints Dr. Porter-Brown as Chief Medical Officer

BTIG, Moonlake Immunotherapeutics hissesi için veri öncesi Al notunu yineliyor